Skip to Content

'
Isabelle Bedrosian, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Member of the Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

1994 Northwestern University Medical School, Chicago, IL, MD, with distinction, Medicine
1989 Tufts University, Medford, MA, BS, summa cum laude, Biology

Postgraduate Training

6/2004 Clinical Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
6/2001 Clinical Residency, Surgery, University of Pennsylvania, Philadelphia, PA

Board Certifications

2/2002 American Board of Surgery

Honors and Awards

2011-present Castle Connolly Top Doctor, Castle Connolly Medical Ltd
2009 Early Career Women's Faculty Development Award, Association of American Medical College (AAMC)
2007 Texas Federation of Business & Professional Women
2006 Faculty Research Fellowship Award, The American College of Surgeons
2005 Foundation Award, The Lehman Brothers Foundation
2002 Oncology Fellowship Award for Basic Research, James Ewing Foundation
2000 Young Investigator Award, American Association for Cancer Research (AACR)
1993 Alpha Omega Alpha, Northwestern University Medical School
1991 Biochemistry Department Sigmund S. Winton Award, Northwestern University Medical School
1989 Alumni Association Senior Award, Tufts University
1988 Alpha Xi Delta Prize Scholarship, Tufts University
1988 Phi Beta Kappa, Tufts University

Professional Memberships

Alliance for Clinical Trials in Oncology, IL
Vice Chair of the Cancer Prevention Committee, 2011-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I , Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of Internal Mammary Lymph Node Drainage Identified by Preoperative Lymphoscintigraphy on Outcomes in Patients with Stage I to III Breast Cancer. Cancer. e-Pub 5/2012. PMID: 22648744.
2. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I , Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective Evaluation of the Nipple-Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer. Ann Surg Oncol 19(4):1137-44, 4/2012. e-Pub 10/2011. PMID: 21979111.
3. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I , Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence after Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol 19(3):901-7, 3/2012. e-Pub 8/2011. PMID: 21861223.
4. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I , Dawood S, Arun B, Albarracin CT. Invasive Paget Disease of Breast: Clinicopathologic Study of an Under-Recognized Entity in the Breast. Am J of Surg PathoL 36(9):1353-8, 2012. PMID: 22895267.
5. Bedrosian I , Hu CY, Chang GJ. Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. J Natl Cancer Inst 102(6):401-409, 3/2010. e-Pub 2/2010. PMID: 20185801.
6. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I . Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115(3):651-9, 6/2009. e-Pub 12/2008. PMID: 19107593.
7. Bedrosian I , Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E associated kinase activity predicts response to platinum based chemotherapy. Clin Cancer Res 13(16)(16):4800-4806, 8/2007. PMID: 17699858.
8. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I . Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7)(7):1440-1447, 10/2006. PMID: 16955504.
9. Bedrosian I , Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23(15):2648-57, 4/2004. PMID: 15007381.

Invited Articles
1. Dominici LS, Mittendorf EA, Yu TK, Bedrosian I . Impact of breast cancer subtypes on local-regional outcomes. Current Breast Cancer Reports. In Press.

Grant & Contract Support

Title: Does IGF-1 signaling sensitize mammary epithelial cells to oncogene induced DNA damage and increase breast cancer risk
Funding Source: Society of Surgical Oncology
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2013

Last updated: 2/28/2013